Bortezomib vs Carfilzomib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Bortezomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule (proteasome inhibitor)
Partial signal

NCT00048230 · Phase 3 · completed

APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)

Result source: NCT00722566

Carfilzomib

Marketed by Amgen and partners

Approved in Multiple Myelomasmall molecule
Partial signal

NCT01080391 · Phase 3 · completed

The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).

Next expected readout: November 2026 · NCT04973605 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)

Result source: NCT03158688

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBortezomibCarfilzomib
PFS, median11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
OS, median83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results
ORR90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284
VGPR or better71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565

PFS, median

Bortezomib
11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
Carfilzomib
26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284

OS, median

Bortezomib
83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
Carfilzomib
10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results

ORR

Bortezomib
90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
Carfilzomib
82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284

VGPR or better

Bortezomib
71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
Carfilzomib
72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results

MRD negativity

Bortezomib
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
Carfilzomib
18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety

Coverage. Bortezomib: 24 of 24 rows · Carfilzomib: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBortezomib
Rows use multiple source trials
Carfilzomib
Rows use multiple source trials
Complete
responder rate · % of participants
53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
10.7% (n=131) vs 7.3% (n=137) placebo
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasonea,b
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
2 other source trials
28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasone
NCT03158688 · Phase 3 · combination
25.9% (n=478) vs 23.1% (n=477) Bortezomib, Melphalan, Prednisone
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
Complete
responder rate · % of participants
No placebo or comparator arm
8.2% (n=73)*c,d,a,e
NCT00722566 · Phase 3 · converted to % from 6 Participants as posted
show 1 more dose
6.2% (n=145)*
NCT00722566 · Phase 3 · converted to % from 9 Participants as posted
21.95% (n=41)Dose Level 3c,d,a,e
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
17.07% (n=41) @ 14.285714wkDose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Complete
responder rate · % of participants
No placebo or comparator arm
Complete response
14.3% (n=7)*f,a,b
Complete response
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=42)*c,f,a,b
NCT00511238 · Phase 2 · converted to % from 0 participants as posted
show 1 more dose
0.4% (n=257)*
NCT00511238 · Phase 2 · pooled · converted to % from 1 participants as posted
CR/sCR
responder rate · % of participants
No placebo or comparator arm
55.2% (n=67)c,a,b
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
show 2 more doses
16.4% (n=67)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
50.8% (n=65)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
55.2% (n=67)c,a,b
NCT03412565 · Phase 2 · combination
show 3 more doses
16.4% (n=67)
NCT03412565 · Phase 2 · combination
42.4% (n=66)
NCT03412565 · Phase 2 · combination
50.8% (n=65)
NCT03412565 · Phase 2 · combination
Duration of Response
time to event · months
NA vs 21.3 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
3 other source trials
13.7 vs 10.94 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
17.28 vs 12.88 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) monthsa,b
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
4 other source trials
7.2 vs 9.5 placebo months
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
NA vs NA Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
21.3 vs 10.4 Bortezomib months
NCT01568866 · Phase 3 · combination
NA vs 16.6 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
Duration of Response
time to event · months
No placebo or comparator arm
18.3 monthsc,f,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
19.8 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
22.4 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
NA monthsc,f,a,b
NCT03412565 · Phase 2 · combination
show 2 more doses
NA months
NCT03412565 · Phase 2 · combination
NA months
NCT03412565 · Phase 2 · combination
EORTC QLQ-C30 GHS
absolute change · score
9.8 vs 8.9 Velcade, Melphalan and Prednisone score @ 208wka,g
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
65.1 vs 62.9 Bortezomib, Melphalan, Prednisone score @ 48wka,g
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
Minimal
responder rate · % of participants
No placebo or comparator arm
Minimal response
14.3% (n=14)*f,a,b
Minimal response
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
7.1% (n=42)*c,f,a,b
NCT00511238 · Phase 2 · converted to % from 3 participants as posted
show 1 more dose
13.2% (n=257)*
NCT00511238 · Phase 2 · pooled · converted to % from 34 participants as posted
MRD Negative
responder rate · % of participants
No placebo or comparator arm
25.4% (n=67)c,a,b
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
21.5% (n=65)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
25.4% (n=67)c,a,b
NCT03412565 · Phase 2 · combination
show 2 more doses
27.3% (n=66)
NCT03412565 · Phase 2 · combination
21.5% (n=65)
NCT03412565 · Phase 2 · combination
ORR
responder rate · % of participants
No placebo or comparator arm
19% (n=63)a,b
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
7 other source trials
73% (n=147)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
70% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
80% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
88.1% (n=67)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
97% (n=67)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
90.8% (n=65)
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
80.6% (n=31) @ 24wk
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
62.9% (n=240)20/70 mg/m² once weeklyc,a,b
NCT02412878 · Phase 3 · combination
show 1 more dose
40.8% (n=238)20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
Overall Survival
time to event · months
No placebo or comparator arm
33 monthsc,a,b
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
30.8 months
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
NA months20/70 mg/m² once weeklyc,a,b
NCT02412878 · Phase 3 · combination
show 1 more dose
NA months20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
Partial
responder rate · % of participants
No placebo or comparator arm
Partial Response
28.6% (n=7)*c,f,a,b
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 2 more doses
60% (n=5)*
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
21.4% (n=14)*
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
16.7% (n=42)*c,f,a,b
NCT00511238 · Phase 2 · converted to % from 7 participants as posted
show 1 more dose
18.3% (n=257)*
NCT00511238 · Phase 2 · pooled · converted to % from 47 participants as posted
PFS
time to event · months
No placebo or comparator arm
52.8 monthsc,a,e,b
NCT02541383 · Phase 3 · registry result, not featured evidence
show 1 more dose
46.7 months
NCT02541383 · Phase 3 · registry result, not featured evidence
11.2 months20/70 mg/m² once weeklyc,a,e,b
NCT02412878 · Phase 3 · combination
show 1 more dose
7.6 months20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
PFS2
time to event · months
66.73 vs 42.41 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
47.18 vs 35.58 Carfilzomib + Dexamethasone monthsc,a,b
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more dose
47.18 vs 32.36 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Stable Disease
event count · % of participants
No placebo or comparator arm
Stable disease
14.3% (n=7)*c,f,a,e,b
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 2 more doses
20% (n=5)*
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
7.1% (n=14)*
NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
33.3% (n=12)*f,a,e,b
Stable Disease
NCT01775553 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
Time to Progression
time to event · months
NA vs 19.35 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
3 other source trials
NA vs 7.29 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
9.9 vs 12.6 Bortezomib + Dexamethasone months
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
NA vs 20.27 Carfilzomib + Dexamethasone monthsa,b
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
NA vs 17.5 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
Time to Progression
time to event · months
No placebo or comparator arm
9.3 monthsc,d,h,b
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
6.5 months
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
9.4 months20/70 mg/m²c,d,h,b
NCT00531284 · Phase 1/2
show 18 more doses
1 months20/70 mg/m²
NCT00531284 · Phase 1/2
1.6 months20/70 mg/m²
NCT00531284 · Phase 1/2
NA months20/70 mg/m²
NCT00531284 · Phase 1/2
6.9 months20/56 mg/m²
NCT00531284 · Phase 1/2
11.5 months20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
NA months20/56 mg/m²
NCT00531284 · Phase 1/2
1.6 months20/56 mg/m²
NCT00531284 · Phase 1/2
NA months20/56 mg/m²
NCT00531284 · Phase 1/2
4.6 months20/45 mg/m²
NCT00531284 · Phase 1/2
4.6 months20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
1.6 months20/45 mg/m²
NCT00531284 · Phase 1/2
1.6 months45 mg/m²
NCT00531284 · Phase 1/2
5.2 months20/36 mg/m²
NCT00531284 · Phase 1/2
1.8 months20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
1.7 months36 mg/m²
NCT00531284 · Phase 1/2
1.8 months20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
1.8 months20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
5.1 months20 mg/m² Bolus
NCT00531284 · Phase 1/2
Time to Response
time to event · months
0.79 vs 0.82 Velcade, Melphalan and Prednisone monthsa,b
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
1.41 vs 1.61 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
1.4 vs 1.5 Carfilzomib and Dexamethasone monthsa,b
NCT03158688 · Phase 3 · combination
Time to Response
time to event · months
No placebo or comparator arm
1.4 monthsi,a,b
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
2.6 monthsc,i,a,b
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
2.8 months
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
VGPR or Better
responder rate · % of participants
No placebo or comparator arm
37% (n=147)c,f,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
41% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
51% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
77.6% (n=67)c,f,a,b
NCT03412565 · Phase 2 · combination
show 3 more doses
71.6% (n=67)
NCT03412565 · Phase 2 · combination
77.3% (n=66)
NCT03412565 · Phase 2 · combination
80% (n=65)
NCT03412565 · Phase 2 · combination
Dropout rate
47.3%VELCADE Intravenousj
NCT00722566 · Phase 3
show 32 more results
45.3%VELCADE Subcutaneous
NCT00722566 · Phase 3
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
1.1%Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
15%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01109004 · Phase 3 · registry result, not featured evidence
20.7%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneVelcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
70.2%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.3%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
74.9%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.1%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
64.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02703779 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePart 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
87.1%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
1%k
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
0.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
89.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
5.4%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
8.8%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
67.3%
NCT03158688 · Phase 3 · combination
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
77.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
57.1%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/45 mg/m²
NCT00531284 · Phase 1/2
85.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/45 mg/m²
NCT00531284 · Phase 1/2
100%45 mg/m²
NCT00531284 · Phase 1/2
100%20/36 mg/m²
NCT00531284 · Phase 1/2
85.7%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%36 mg/m²
NCT00531284 · Phase 1/2
96.9%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20 mg/m² Bolus
NCT00531284 · Phase 1/2
91.3%Carfilzomib (A0)
NCT00511238 · Phase 2
85%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
58.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
74.3%20 mg/m²
NCT00530816 · Phase 2
71.2%20 mg/m²
NCT00530816 · Phase 2
92.3%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
65.3%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
16.2%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
78.6%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
41.4%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
11.1%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
19.7%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01775553 · Phase 2 · registry result, not featured evidence
20.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
80%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
2.8%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
93.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
95.5%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
66.7%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
100%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—VELCADE Intravenousj
NCT00722566 · Phase 3
show 32 more results
—VELCADE Subcutaneous
NCT00722566 · Phase 3
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
—
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
0.5%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
—
NCT01109004 · Phase 3 · registry result, not featured evidence
5.5%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
—Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
34.5%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
38.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
40.1%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
31.9%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
—
NCT02703779 · Phase 2 · registry result, not featured evidence
33.3%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
19%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
64.5%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
—k
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
—
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
16.2%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
20.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
—20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
—20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
—
NCT03158688 · Phase 3 · combination
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
—Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
14.3%20/70 mg/m²
NCT00531284 · Phase 1/2
0%20/70 mg/m²
NCT00531284 · Phase 1/2
27.3%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
25%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
20%20/56 mg/m²
NCT00531284 · Phase 1/2
20.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/45 mg/m²
NCT00531284 · Phase 1/2
28.6%45 mg/m²
NCT00531284 · Phase 1/2
0%20/36 mg/m²
NCT00531284 · Phase 1/2
14.3%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
0%36 mg/m²
NCT00531284 · Phase 1/2
10.8%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
0%20 mg/m² Bolus
NCT00531284 · Phase 1/2
28.3%Carfilzomib (A0)
NCT00511238 · Phase 2
12.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
10%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
17.1%20 mg/m²
NCT00530816 · Phase 2
22%20 mg/m²
NCT00530816 · Phase 2
—Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
15.5%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
—
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
—low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
—high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT01775553 · Phase 2 · registry result, not featured evidence
9.1%
NCT01351623 · Phase 2 · registry result, not featured evidence
37.5%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
8.3%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
40%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
25%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
0%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
13.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
14.6%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Serious AEs
35.1%VELCADE Intravenousj
NCT00722566 · Phase 3
show 32 more results
36.1%VELCADE Subcutaneous
NCT00722566 · Phase 3
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
53.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
55.1%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
63.7%Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
55.9%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
42.4%SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
20.6%
NCT01109004 · Phase 3 · registry result, not featured evidence
34.6%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
27.2%Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
37.7%Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
33%Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
53.3%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
58.2%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
29.8%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
100%
NCT01801436 · Phase 3 · registry result, not featured evidence
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
46.5%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
48%
NCT02703779 · Phase 2 · registry result, not featured evidence
47.6%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
33.1%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
45.2%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
65.3%k
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
58.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
72.9%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
58.7%Carfilzomib
NCT01568866 · Phase 3
—Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
49.6%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
43.4%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
68.5%
NCT03158688 · Phase 3 · combination
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
33.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
71.4%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
54.5%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
37.5%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/56 mg/m²
NCT00531284 · Phase 1/2
45.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
35.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
83.3%20/45 mg/m²
NCT00531284 · Phase 1/2
57.1%45 mg/m²
NCT00531284 · Phase 1/2
50%20/36 mg/m²
NCT00531284 · Phase 1/2
57.1%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%36 mg/m²
NCT00531284 · Phase 1/2
41.5%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%20 mg/m² Bolus
NCT00531284 · Phase 1/2
43.5%Carfilzomib (A0)
NCT00511238 · Phase 2
47.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
38.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
34.3%20 mg/m²
NCT00530816 · Phase 2
30.5%20 mg/m²
NCT00530816 · Phase 2
38.5%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
22.4%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
37.7%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
32.5%20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
55.3%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
49.6%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
39.1%
NCT02969837 · Phase 2 · registry result, not featured evidence
42.2%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
39.4%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
47.4%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01775553 · Phase 2 · registry result, not featured evidence
63.6%
NCT01351623 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
41.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
33.3%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
65.2%MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
45.7%Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
16.7%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
26.7%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
39.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
33.3%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
j
leukopenia 21.6%
fatigue 20.3%
constipation 14.9%
NCT00722566 · Phase 3
show 29 more results
leukopenia 19.7%
weight decreased 15%
constipation 14.3%
NCT00722566 · Phase 3
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
neutropenia 50.3%
thrombocytopenia 49.7%
anaemia 31.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 59.7%
peripheral sensory neuropathy 50.2%
diarrhoea 36.2%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
neutropenia 54%
peripheral sensory neuropathy 48.2%
thrombocytopenia 39.6%
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 61.5%
nausea 50.3%
fatigue 42.1%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
thrombocytopenia 50%
anaemia 45.5%
nausea 39.4%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
anemia 40%
nausea 35%
platelet count decreased 35%
NCT01146834 · Phase 3 · registry result, not featured evidence
platelet count decreased 100%
anemia 50%
generalized muscle weakness 50%
NCT01146834 · Phase 3 · registry result, not featured evidence
constipation 35.8%
nausea 32.3%
peripheral sensory neuropathy 24.4%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 37.9%
peripheral sensory neuropathy 36.9%
neuropathy peripheral 29.1%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
nausea 47.8%
diarrhoea 44.7%
fatigue 36.2%
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
nausea 39.3%
diarrhoea 38.4%
constipation 30.8%
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
insomnia 5.5%
weight decreased 2.4%
blood sodium decreased 1.8%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
leukopenia 7.4%
platelet count decreased 4.3%
insomnia 3.7%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
hyperuricaemia 5.1%
insomnia 3.8%
cough 3.2%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
fatigue 38.3%
thrombocytopenia 38.3%
diarrhoea 36.2%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 78.6%
white blood cell count decreased 78.6%
platelet count decreased 71.4%
NCT01801436 · Phase 3 · registry result, not featured evidence
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.7%
upper respiratory tract infection 67.7%
diarrhoea 65.7%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
diarrhea 58% (placebo 56.9%)
nausea 58% (placebo 64.7%)
anorexia 54% (placebo 51%)
NCT02703779 · Phase 2 · registry result, not featured evidence
neutropenia 81% (placebo 38.1%)
diarrhoea 61.9% (placebo 36%)
thrombocytopenia 61.9% (placebo 46.8%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
neutropenia 60.6% (placebo 38.1%)
thrombocytopenia 58.5% (placebo 46.8%)
peripheral sensory neuropathy 51.4% (placebo 52.5%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 80.6%
decreased appetite 58.1%
thrombocytopenia 54.8%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
k
diarrhoea 43.4%
anaemia 42.3%
neutropenia 40.1%
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 62 more results
anaemia 56.1% (placebo 47.1%)
thrombocytopenia 36.9% (placebo 28.1%)
pyrexia 26.1% (placebo 18.3%)
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
infusion related reaction 45.2%
upper respiratory tract infection 41.2%
diarrhoea 40.7%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
anaemia 42.3%
diarrhoea 36.1%
fatigue 32.2%
NCT01568866 · Phase 3
20/70 mg/m² once weekly
anaemia 29%
hypertension 24.4%
pyrexia 23.1%
NCT02412878 · Phase 3 · combination
20/27 mg/m² twice weekly
anaemia 31.1%
diarrhoea 21.7%
hypertension 20.9%
NCT02412878 · Phase 3 · combination
thrombocytopenia 38.6%
anaemia 36.7%
hypertension 36.7%
NCT03158688 · Phase 3 · combination
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · combination
thrombocytopenia 51.5%
anaemia 37.9%
hypertension 34.8%
NCT03412565 · Phase 2 · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · combination
20/70 mg/m²
pyrexia 71.4%
blood creatinine increased 57.1%
chills 57.1%
NCT00531284 · Phase 1/2
20/70 mg/m²
fatigue 100%
thrombocytopenia 100%
anaemia 50%
NCT00531284 · Phase 1/2
20/70 mg/m²
nausea 54.5%
fatigue 45.5%
anaemia 27.3%
NCT00531284 · Phase 1/2
20/56 mg/m²
pyrexia 100%
asthenia 66.7%
cough 66.7%
NCT00531284 · Phase 1/2
20/56 mg/m² + Dex
fatigue 62.5%
pyrexia 50%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/56 mg/m²
pyrexia 50%
anaemia 40%
constipation 40%
NCT00531284 · Phase 1/2
20/56 mg/m²
fatigue 58.3%
nausea 54.2%
pyrexia 54.2%
NCT00531284 · Phase 1/2
20/45 mg/m²
fatigue 100%
blood creatinine increased 66.7%
cancer pain 66.7%
NCT00531284 · Phase 1/2
20/45 mg/m² + Dex
fatigue 64.3%
cough 57.1%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/45 mg/m²
chills 50%
fatigue 50%
hypoaesthesia 50%
NCT00531284 · Phase 1/2
45 mg/m²
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT00531284 · Phase 1/2
20/36 mg/m²
fatigue 75%
nausea 75%
anaemia 50%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
asthenia 57.1%
headache 57.1%
nausea 57.1%
NCT00531284 · Phase 1/2
36 mg/m²
chest wall pain 33.3%
dyspnoea 33.3%
nausea 33.3%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
fatigue 58.5%
nausea 43.1%
anorexia 40%
NCT00531284 · Phase 1/2
20/27 mg/m² Bolus
back pain 50%
fatigue 50%
abnormal dreams 25%
NCT00531284 · Phase 1/2
20 mg/m² Bolus
hypomagnesaemia 66.7%
anxiety 33.3%
constipation 33.3%
NCT00531284 · Phase 1/2
anaemia 73.9%
fatigue 69.6%
thrombocytopenia 50%
NCT00511238 · Phase 2
fatigue 48.9%
anaemia 45.9%
nausea 44.7%
NCT00511238 · Phase 2 · pooled
20/27 mg/m²
fatigue 54.3%
nausea 44.3%
anaemia 35.7%
NCT00530816 · Phase 2 · pooled
20 mg/m²
fatigue 62.9%
nausea 60%
vomiting 42.9%
NCT00530816 · Phase 2
20 mg/m²
fatigue 71.2%
nausea 54.2%
dyspnoea 49.2%
NCT00530816 · Phase 2
cough 42.3%
anaemia 36.5%
pyrexia 26.9%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
cough 26.5%
diarrhoea 18.4%
hypertension 18.4%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
20/56 mg/m^2 once weekly
neutropenia 29.1%
anaemia 25.1%
hypertension 21.5%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
20/27 mg/m^2 twice weekly
neutropenia 31.6%
hypertension 24.2%
anaemia 23.8%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
anaemia 61.8%
platelet count decreased 48.8%
upper respiratory tract infection 48.8%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
anaemia 35.4%
pyrexia 35.4%
nausea 35.2%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
fatigue 63%
diarrhea 45.7%
edema limbs 37%
NCT02969837 · Phase 2 · registry result, not featured evidence
lymphocyte count decreased 100%
hypoalbuminemia 93.3%
platelet count decreased 93.3%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
low-dose
anemia 59.1%
fatigue 59.1%
platelet count decreased 42.4%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
high-dose
anemia 66.7%
fatigue 57.9%
platelet count decreased 50.9%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
anemia 61.5%
hypertension 53.8%
platelet count decreased 53.8%
NCT01775553 · Phase 2 · registry result, not featured evidence
diarrhea 65.9%
nausea 59.1%
fatigue 54.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
thrombocytopenia 62.5%
abdominal pain 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 58.3%
constipation 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 70%
fatigue 60%
nausea 60%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 50%
dyspnoea 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
fatigue 50%
dyspnoea 37.5%
NCT00721734 · Phase 2 · registry result, not featured evidence
56mg/m2/Dose
anxiety 33.3%
hyperkalemia 33.3%
hypertension 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
45mg/m2/Dose
lymphocyte count decreased 66.7%
skin infection 66.7%
alanine aminotransferase increased 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
lymphocyte count decreased 73.9%
neutrophil count decreased 65.2%
white blood cell decreased 60.9%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
Dose Level 0
anemia 100%
cd4 lymphocytes decreased 100%
lymphocyte count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 1
anemia 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 2
hypotension 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 3
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
platelet count decreased 100%
lymphocyte count decreased 91.4%
white blood cell decreased 91.4%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
88 mg/m²
headache 66.7%
fatigue 50%
insomnia 50%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
upper respiratory tract infection 80%
diarrhoea 60%
fatigue 60%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
fatigue 52.8%
nausea 40.4%
insomnia 32.6%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
56 mg/m²
anaemia 66.7%
arthralgia 66.7%
cardiac murmur 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
45 mg/m²
fatigue 100%
back pain 66.7%
diarrhoea 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 1/2 versus Phase 3.
  5. eTreatment context has not been resolved for both arms.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gAssessment timepoints differ: 48 weeks versus 208 weeks.
  8. hPopulation context differs: registered conditions differ.
  9. iTrial phases differ: Phase 4 versus Phase 2.
  10. jPopulation comparability has not been reviewed for 30 of these studies.
  11. kPopulation comparability has not been reviewed for 66 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bortezomib

ORR 42.1% (n=145)
event count · % of participants
No placebo or comparator arm
NCT00722566 · Phase 3 · converted to % from 61 Participants as posted
show 1 more result
42.5% (n=73)*
NCT00722566 · Phase 3 · converted to % from 31 Participants as posted
CR/sCR 42.6% (n=350) vs 24.4% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 18% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
23.5% (n=98) vs 20.8% (n=96) Thalidomide + Prednisolone @ 13wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 27.1% (n=96) Thalidomide + Prednisolone @ 26wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
30.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 39wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
42.4% (n=99) vs 32% (n=97) Lenalidomide+Bortezomib+Dexamethasone
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
Time to Next Treatment 66.8 vs 25.9 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
16.13 vs 10.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
EORTC QLQ-C30 Emotional Functioning 8.5 vs 9.4 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
10.8 vs 10.5 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
11.1 vs 11.8 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.6 vs 11.2 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.5 vs 12.8 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.7 vs 11.8 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 10.8 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.3 vs 10.8 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.8 vs 6.5 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.5 vs 6.2 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
EQ-5D-5L VAS 9.37 vs 4.27 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
11.02 vs 7.51 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.51 vs 10.08 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.93 vs 11.1 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
15.35 vs 10.75 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
12.17 vs 10.62 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
14.41 vs 12.38 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
13.94 vs 12 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
14.33 vs 12.88 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
11.93 vs 9.17 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
EQ-5D-5L Index 0.12 vs 0.09 Velcade, Melphalan and Prednisone score @ 13wk
absolute change · score
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 9 more results
0.14 vs 0.12 Velcade, Melphalan and Prednisone score @ 26wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.16 vs 0.16 Velcade, Melphalan and Prednisone score @ 39wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.15 Velcade, Melphalan and Prednisone score @ 52wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.14 Velcade, Melphalan and Prednisone score @ 78wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.18 vs 0.15 Velcade, Melphalan and Prednisone score @ 104wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.19 vs 0.16 Velcade, Melphalan and Prednisone score @ 130wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.21 vs 0.16 Velcade, Melphalan and Prednisone score @ 156wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.2 vs 0.08 Velcade, Melphalan and Prednisone score @ 182wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
0.15 vs 0.07 Velcade, Melphalan and Prednisone score @ 208wk
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 3.2% (n=281) vs 0.7% (n=278) BTZ+LD-DEX
responder rate · % of participants
Stringent complete response
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
Stable Disease 11.4% (n=281) vs 38.1% (n=278) BTZ+LD-DEX
event count · % of participants
Stable Disease
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
Progressive Disease 3.9% (n=281) vs 5.8% (n=278) BTZ+LD-DEX
event count · % of participants
Progressive Disease
NCT01734928 · Phase 3 · registry result, not featured evidence · combination · converted to % from 11 Participants as posted
CD34 6e6 Mobilization up to 2 Apheresis 64.7% (n=17) vs 66.7% (n=21) CYCLOPHOSPHAMIDE & G-CSF @ 156wk
event count · % of participants
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
show 1 more result
0% (n=4) vs 66.7% (n=21) CYCLOPHOSPHAMIDE & G-CSF @ 156wk*
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
Neutrophil Recovery 100% (n=7) vs 100% (n=11) CYCLOPHOSPHAMIDE & G-CSF @ 2.86wk
event count · % of participants
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 1 more result
100% (n=4) vs 100% (n=11) CYCLOPHOSPHAMIDE & G-CSF @ 2.86wk*
NCT01146834 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted

+ 29 further endpoints in the CSV export.

Carfilzomib

Disease Control 92.7% (n=396) vs 87.1% (n=396) Lenalidomide and Dexamethasone (Rd)
responder rate · % of participants
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Disease Control 28.7 vs 18.9 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 19.1% (n=157) vs 11.4% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 30 participants as posted
Clinical Benefit 31.2% (n=157) vs 20.9% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 49 participants as posted
VGPR or Better With MRD Negativity 29.6% (n=179) vs 13% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
33.5% (n=179) vs 13.8% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete Response With MRD Negativity 26.3% (n=179) vs 12.2% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
12.8% (n=312) vs 1.9% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · combination
Complete Renal 52% (n=25) vs 30.8% (n=13) Carfilzomib + Dexamethasone
responder rate · % of participants
CR Renal
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 13 Participants as posted
Time to Next Treatment NA vs 17.3 Carfilzomib and Dexamethasone months
time to event · months
PA DCO
NCT03158688 · Phase 3 · combination
TTP 95.3% (n=312) vs 90% (n=154) Carfilzomib and Dexamethasone @ 13wk
responder rate · % of participants
NCT03158688 · Phase 3 · combination
show 3 more results
86.4% (n=312) vs 79.4% (n=154) Carfilzomib and Dexamethasone @ 26wk
NCT03158688 · Phase 3 · combination
77.5% (n=312) vs 62.7% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · combination
68.5% (n=312) vs 45.1% (n=154) Carfilzomib and Dexamethasone @ 78wk
NCT03158688 · Phase 3 · combination
Sustained MRD Negative CR 0% (n=312) vs 0% (n=154) Carfilzomib and Dexamethasone
responder rate · % of participants
PA DCO
NCT03158688 · Phase 3 · combination
EORTC QLQ-C30 GHS 61 vs 64.35 Carfilzomib and Dexamethasone score @ 4wk
absolute change · score
Cycle 2
NCT03158688 · Phase 3 · combination
EORTC QLQ-C30 GHS 63.1 vs 66.13 Carfilzomib and Dexamethasone score @ 8wk
absolute change · score
Cycle 3
NCT03158688 · Phase 3 · combination

+ 93 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Carfilzomib's landscape